Beta Bionics (NASDAQ:BBNX) Stock Price Breaks Below 200-Day Moving Average - Here's What Happened

Beta Bionics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Beta Bionics shares fell below their 200-day moving average of $14.86, trading as low as $14.55 and last at $14.72.
  • Analysts maintain a “Moderate Buy” consensus with an average price target of $23.69, though ratings range from strong buy to sell.
  • The company’s latest quarterly loss per share of $0.52 slightly beat estimates, while insiders sold a combined 103,069 shares over the past three months.
  • Five stocks we like better than Beta Bionics.

Shares of Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $14.86 and traded as low as $14.55. Beta Bionics shares last traded at $14.72, with a volume of 1,075,548 shares traded.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BBNX. Bank of America upped their price target on Beta Bionics from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Tuesday, September 15th. Truist Financial raised their price objective on Beta Bionics from $23.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, September 24th. Wall Street Zen lowered shares of Beta Bionics from a "hold" rating to a "strong sell" rating in a report on Saturday, October 31st. Jefferies Financial Group initiated coverage on shares of Beta Bionics in a research report on Monday, October 12th. They issued a "buy" rating and a $30.00 target price on the stock. Finally, TD Cowen increased their target price on shares of Beta Bionics from $18.00 to $21.00 and gave the stock a "hold" rating in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Beta Bionics presently has an average rating of "Moderate Buy" and an average target price of $23.69.

Get Our Latest Research Report on BBNX

Beta Bionics Stock Down 3.2%

The firm has a 50-day moving average price of $18.29 and a 200 day moving average price of $14.86. The firm has a market capitalization of $800.33 million, a PE ratio of -8.00 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The firm had revenue of $35.51 million for the quarter. Equities research analysts expect that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.

Insider Activity at Beta Bionics

In related news, insider Mark Hopman sold 30,779 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total value of $619,581.27. Following the completion of the transaction, the insider owned 56,479 shares in the company, valued at approximately $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the completion of the transaction, the director owned 19,564 shares of the company's stock, valued at $449,972. This trade represents a 24.74% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 103,069 shares of company stock valued at $2,014,358. 5.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Beta Bionics

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Beta Bionics during the 2nd quarter worth about $52,340,000. Eversept Partners LP raised its position in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock valued at $14,177,000 after purchasing an additional 736,576 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Beta Bionics in the 2nd quarter valued at about $8,566,000. Perceptive Advisors LLC boosted its stake in shares of Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company's stock valued at $8,446,000 after buying an additional 240,000 shares during the period. Finally, Bruce & Co. Inc. purchased a new position in shares of Beta Bionics in the 1st quarter valued at about $5,518,000.

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user's body weight and adjusts insulin delivery based on glucose readings.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines